With cervical cancer often diagnosed at an advanced stage—leading to poor survival rates—India accounts for 25% of global ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

Truenat HPV-HR Plus is designed to work with cervical swab samples collected by a clinician, it gives highly accurate results in just 60 minutes. Easy to use and with high stability at room ...

Cervical cancer symptoms are often absent in the early stages and may only become apparent when the disease is more advanced. Abnormal vaginal bleeding is the most common symptom overall, often ...

Cancer Res (2025) 85 (8_Supplement_1): 4663. Human papillomavirus (HPV) DNA is detectable in the peripheral blood plasma from patients with locally advanced and metastatic cervical cancer. Levels of ...

Updated phase 3 data support pembrolizumab plus concurrent chemoradiotherapy as a standard of care for patients with high-risk, locally advanced cervical cancer, according to Linda Duska, MD.

DelveInsight’s, “Advanced Cervical Cancer Pipeline Insight 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Advanced Cervical Cancer pipeline landscape.

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or ...

Keytruda is currently the only PD-1/PD-L1 inhibitor approved for advanced cervical cancer, one of the most common tumour types in women with 14,500 new cases diagnosed every year in the US, and ...

“It is very reassuring,” said lead author Recinda Sherman of the North American Association of Central Cancer Registries. “So ...

The National Academy of Medical Sciences (NAMS) has recommended categorising cancer as a notifiable disease to improve ...